Pulmonary artery pressure matters – how to efficiently improve survival in pulmonary arterial hypertension (RCD code: II‐1A.1)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2017, Vol 3, Issue 4
Abstract
Pulmonary arterial hypertension is a disease characterized by poor prognosis despite treatment. Even in a modern era of pharmaco- therapy there is a strong need to further improve survival of patients. The current therapeutic strategies do not offer a real break-through in terms of reducing mortality. In a search for better efficacy of treatment we discuss a strategy based on lowering pulmonary artery pressure as much as possible with epoprostenol in monotherapy or in combination. Epoprostenol with bosentan is an effective tool in achieving this goal. A rapid up-titration regardless of maximum epoprostenol dose achieved gives additional long-term benefit. Practical issues related to such modality of treatment are also discussed. JRCD 2017; 3 (4): 110–115
Authors and Affiliations
Hiromi Matsubara, Piotr Błaszczak, Grzegorz Kopeć
Keywords
Related Articles
- EP ID EP245512
- DOI 10.20418/jrcd.vol3no4.295
- Views 89
- Downloads 0
Doxorubicin cardiomyopathy – case report and review of histopathologic findings (RCD code: III‐1B.5a)
The anthracycline anticancer drug Doxorubicin (Adriamycin) is an effective and frequently used chemotherapeutic agent for various malignancies. The use of doxorubicin is limited by its major adverse effect, cardiotoxicit...
Exercise capacity in adult patients after Fontan procedure. (RCD code: IV-5B.1)
Background: The aim of Fontan procedure is to restore a balance between pulmonary and systemic circulation and improve or nearly normalize arterial saturation in patients with functionally univentricular heart. Neverthel...
Brugada syndrome: 2017 update. (RCD code: V-1A.1)
N/A
Current views on the use of interferons in the treatment of polycythaemia vera
Interferon alpha is a molecule associated with stimulation of immune system cells, resulting in an anti‐proliferative and immunomodulatory effect. It has been demonstrated that interferon reduces the number of platelets,...
A 50-year-old unrepaired patient with pulmonary atresia and ventricular septal defect
Pulmonary atresia with ventricular septal defect (PA + VSD) is a cyanotic congenital heart disease, also classified as Tetralogy of Fallot with pulmonary atresia. PA + VSD accounts for about 1–2% of congenital heart defe...